FEG Investment
Advisors

Where's the Promise of Biotech? Featuring Peter Kolchinsky

This month, Peter Kolchinsky of RA Capital joins Greg to discuss biotech innovation and investment strategy, and where science will take society next.

In this episode of the FEG Insight Bridge Podcast, Greg Dowling speaks with Peter Kolchinsky, Managing Partner at RA Capital. Together they delve into the drivers and details of today’s biotech industry, how to foster innovation and why Peter is optimistic about biotech’s ability to address autoimmune disorders. Peter shares RA Capital’s investment approach, which emphasizes patience, rigor and selectiveness across healthcare and life science sectors.

Listen to an insightful, actionable discussion on the forces shaping biotech investing today and likely to shape it tomorrow.

 

Key Takeaways:

  • Peter emphasizes the importance of fostering innovation, especially in the biopharmaceutical industry.
  • RA Capital’s investment philosophy centers on long-term value creation, focusing on select companies within the space that address significant unmet medical needs and have strong scientific foundations.
  • Kolchinsky critiques current drug pricing debates, arguing that attempts to control costs in the short term could harm future innovation and patient outcomes.
  • Despite vaccine concerns, political uncertainty and the continual headwind of expiring patents, Peter’s outlook for biotech — especially the potential to address autoimmune disorders — is strong.




Episode Chapters
0:00 Podcast Introduction
1:17 Introduction to RA Capital
2:13 Inspiration for Biotech Investing 
5:28 Today's Biotech Opportunity 
7:53 Benefits of Active Management
9:23 Defining the Biotech Investment Universe
10:35 As a Sector Specialist, How Do You Look at Biotech Companies Differently?
14:05 Big Pharma's Impact on Biotech M&A
19:14 What is Tech Atlas?
23:04 The Tech Atlas Process in Action
26:36 How Federal Policy is Shaping Healthcare Regulation and Drug Approvals
30:55 Outlook and Why RA Capital Remains Optimistic
34:41 Biotech Book Recommendation and Peter's Fun Fact

 

Disclosures

This information was prepared by Fund Evaluation Group, LLC (FEG), a federally registered investment adviser under the Investment Advisers Act of 1940, as amended, providing non-discretionary and discretionary investment advice to its clients on an individual basis. Registration as an investment adviser does not imply a certain level of skill or training. The oral and written communications of an adviser provide you with information about which you determine to hire or retain an adviser. Fund Evaluation Group, LLC, Form ADV Part 2A & 2B can be obtained by written request directed to: Fund Evaluation Group, LLC, 201 East Fifth Street, Suite 1600, Cincinnati, OH 45202 Attention: Compliance Department.

This information is prepared for informational purposes only. It does not address specific investment objectives, or the financial situation and the particular needs of any person who may receive this presentation. Neither the information nor any opinion expressed in this report constitutes an offer, or an invitation to make an offer, to buy or sell any securities.

The information herein was obtained from various sources. FEG does not guarantee the accuracy or completeness of such information provided by third parties. The information in this presentation is given as of the date indicated and believed to be reliable. FEG assumes no obligation to update this information, or to advise on further developments relating to it.